Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Transducin (Β)-Like 1 X-linked Receptor 1 Promotes Proliferation and Tumorigenicity in Human Breast Cancer Via Activation of Beta-Catenin Signaling

TBLR1 is a Novel Prognostic Marker and Promotes Epithelial–mesenchymal Transition in Cervical Cancer

TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer

TBL1XR1 Induces Cell Proliferation and Inhibit Cell Apoptosis by the PI3K/AKT Pathway in Pancreatic Ductal Adenocarcinoma.

Transducin (Beta)-Like 1 X-Linked Receptor 1 Correlates with Clinical Prognosis and Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma

Transducin (Β)-Like 1 X-linked Receptor 1 Promotes Gastric Cancer Progression Via the ERK1/2 Pathway

TBL1XR1 promotes the migration and invasion of ovarian cancer cells by upregulating Wnt/β-catenin signaling pathway

Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target

TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma.

Nuclear Tblr1 As an Er Corepressor Promotes Cell Proliferation, Migration and Invasion in Breast and Ovarian Cancer

TBL1X: At the crossroads of transcriptional and posttranscriptional regulation

TBP activates DCBLD1 transcription to promote cell cycle progression in cervical cancer

Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling

TBL1XR1 Predicts Isolated Tumor Cells and Micrometastasis in Patients with TNM Stage I/II Colorectal Cancer

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Regulation of the β‐catenin/LEF‐1 pathway by the siRNA knockdown of RUVBL1 expression inhibits breast cancer cell proliferation, migration and invasion

ITGBL1 is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway.

TC-1 (c8orf4) Enhances Aggressive Biologic Behavior in Lung Cancer Through the Wnt/β-catenin Pathway.

TNFRSF11B Promotes the Progression of Bladder Cancer Through PI3K/AKT Signaling Pathway

BCL9/BCL9L Promotes Tumorigenicity Through Immune-Dependent and Independent Mechanisms in Triple Negative Breast Cancer

WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling